Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more

Recent & Breaking News (NDAQ:GLYC)

GlycoMimetics’ GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia

Business Wire May 17, 2017

GlycoMimetics Reports Program Updates and First Quarter 2017 Results

Business Wire May 8, 2017

GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma

Business Wire May 2, 2017

GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting

Business Wire April 20, 2017

GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors

Business Wire March 13, 2017

GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271

Business Wire March 7, 2017

GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017

Business Wire March 1, 2017

GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results

Business Wire March 1, 2017

GlycoMimetics to Present at Cowen 37th Annual Health Care Conference

Business Wire February 28, 2017

GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML

Business Wire December 5, 2016

GlycoMimetics to Present at Upcoming Healthcare Investor Conferences

Business Wire November 10, 2016

GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting

Business Wire November 8, 2016

GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development

Business Wire November 4, 2016

Data from Three GlycoMimetics Drug Candidates to Be Highlighted at 58th Annual American Society of Hematology (ASH) Meeting

Business Wire November 3, 2016

GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma

Business Wire September 14, 2016

GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359

Business Wire September 6, 2016

GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack

Business Wire August 16, 2016

GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference

Business Wire August 8, 2016

GlycoMimetics Reports Second Quarter 2016 Results

Business Wire August 4, 2016

GlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia

Business Wire June 28, 2016